The Centers for Medicare & Medicaid Services (CMS) is considering whether to lift current data-reporting requirements on Sodium Fluoride F-18 (NaF-18) PET for bone metastasis in cancer.
CMS currently covers the procedure only if data on its use are included in a clinical registry begun in 2011 under the agency’s Coverage with Evidence Development (CED) program. The agency’s reconsideration of that requirement comes in response to a request by the physicians who have directed the registry. They argue that the large volume of data collected to date demonstrate the value of using the procedure in guiding cancer care, thus making the registry unnecessary. Through 2014, the registry had collected data from 35,468 scans performed on 28,713 patients, according to the physicians.
CMS is now soliciting public comments through April 15, 2015 and says it expects to make a decision in September.
Click to view the CMS announcement, which includes a link for public comment.